AVENIO Tumor Tissue Expanded Kit V2

RUO For Research Use Only. Not for use in diagnostic procedures.

Extensive range of genes and emerging biomarkers for the profiling of solid tumors

The AVENIO Tumor Tissue Expanded Kit V2 is an NGS research use only assay for expanded profiling of solid tumors in formalin-fixed paraffin-embedded (FFPE) tissue samples. This assay contains 77 genes in the U.S. National Comprehensive Cancer Network (NCCN)1 and other guidelines, plus 60 emerging biomarkers investigated in clinical trials.

Benefits at a glance

Benefits at a glance

AVENIO Tumor Tissue Expanded Kit V2 analytical performance

View full table

AVENIO Tumor Tissue Expanded Kit V2 analytical performance

Mutation class

SNVs

Indels

Fusions

CNVs

Mutant allele frequency/copy number

5%

5%

5%

Sample dependent*

Sensitivity and PPV

Sensitivity

PPV

Sensitivity

PPV

Sensitivity

PPV

>99%

>99%

>99%

>99%

>99%

>99%

 

* The kit reports ERBB2, EGFR, and MET CNVs. Performance is dependent on various factors, including sample type, input DNA amount, percent tumor content, and the individual tumor’s genomic copy number. Our technical study detected CNVs at dPCR-verified copy numbers, using a commercially available reference sample (50 ng). CNV specificity was high (PPV >99%). ERBB2 detected at 4.5 copies, MET detected at 4.5 copies.
Samples: FFPE tissue curls/sections, DNA input: ≥20 ng of FFPET DNA, total DNA amount for each sample determined by input QC.
Sensitivity and Positive Predictive Value (PPV) metrics based on observed product performance.
Sensitivity and PPV performance reported per variant. Sensitivity was determined using commercially available reference samples containing verified mutations at the stated allele frequencies. SNV performance is panel wide. Indel, Fusion based on whitelist variants. AVENIO Tumor Tissue Analysis Kits V2 achieve >99.99% per base specificity across each of the panels. Stated performance requires at least 20 million reads per sample for Targeted, Expanded, and Surveillance Kits V2. Sequencing performed on an Illumina NextSeq 500/550/550Dx (Research Use Only mode) instrument.

Use left and right arrow keys to scroll between the tabs

Overview

Ordering information

error errorMessage
Sorry, we couldn't find the content you are looking for
Please try again later

Key product features

NCCN guideline genes: The assay includes genes in the U.S. National Comprehensive Cancer Network (NCCN) Guidelines1 and other guidelines.

Emerging biomarkers: The assay includes 60 emerging biomarkers investigated in clinical trials.

All mutation classes: All four mutation classes (SNVs, indels, fusions, and CNVs) are included in a single DNA workflow.

Compatible products

No products found for this filter.
No products found for this filter.

Contact us

Do you have any questions about our products or services? We’re here to help. Fill out the form to have a Roche representative contact you.

AVENIO assays are for Research Use Only. Not for use in diagnostic procedures.

References

  1. National Comprehensive Cancer Network [Internet; cited 2025 Nov 20]. Available from: https://www.nccn.org/
  2. F. Hoffmann-La Roche Ltd. Data on file.